We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.68%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$2.63B
AUM Growth
+$312M
Cap. Flow
+$315M
Cap. Flow %
11.96%
Top 10 Hldgs %
49.1%
Holding
89
New
29
Increased
24
Reduced
12
Closed
15

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$69M
2
BIIB icon
Biogen
BIIB
+$42.3M
3
AXSM icon
Axsome Therapeutics
AXSM
+$34.6M
4
ALC icon
Alcon
ALC
+$31.7M
5
INSM icon
Insmed
INSM
+$29.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.6M
2
ABBV icon
AbbVie
ABBV
+$72.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$71.9M
4
AZN icon
AstraZeneca
AZN
+$69.4M
5
LLY icon
Eli Lilly
LLY
+$66.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
76
Amylyx Pharmaceuticals
AMLX
$2.05B
– –
-527,099
Closed -$6.37M
APGE icon
77
Apogee Therapeutics
APGE
$10.2B
– –
-534,845
Closed -$40.4M
CDTX
78
DELISTED
Cidara Therapeutics
CDTX
– –
-180,265
Closed -$39.8M
CNTA
79
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,104,274
Closed -$27.6M
EXAS
80
DELISTED
Exact Sciences
EXAS
– –
-101,443
Closed -$10.3M
GEHC icon
81
GE HealthCare
GEHC
$27.6B
– –
-160,876
Closed -$13.2M
GKOS icon
82
Glaukos
GKOS
$9.02B
– –
-288,128
Closed -$32.5M
ISRG icon
83
Intuitive Surgical
ISRG
$121B
– –
-126,968
Closed -$71.9M
LLY icon
84
Eli Lilly
LLY
$1.07T
– –
-61,652
Closed -$66.3M
MASI
85
DELISTED
Masimo
MASI
– –
-46,201
Closed -$6.01M
QURE icon
86
uniQure
QURE
$2.68B
– –
-176,513
Closed -$4.22M
RNAM
87
DELISTED
Avidity Biosciences
RNAM
– –
-745,116
Closed -$53.7M
VRTX icon
88
Vertex Pharmaceuticals
VRTX
$121B
– –
-164,594
Closed -$74.6M
EVMN
89
Evommune Inc
EVMN
$409M
– –
-153,320
Closed -$2.62M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2026 Portfolio in Review

As of Q1 2026, Sofinnova Investments held 89 positions worth $2.63B, up 13% from $2.32B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sofinnova Investments deployed $315M of net new capital in Q1 2026, opening 29 new positions and adding to 24 existing holdings. Its largest new stake was Biogen: 229,521 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was AstraZeneca, an estimated $69.4M trimmed.

  • Sofinnova Investments's largest Q1 2026 buy was Biogen: 229,521 shares worth $42.1M.
  • Sofinnova Investments added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $69M increase.
  • Sofinnova Investments's biggest Q1 2026 reduction was AstraZeneca, cutting an estimated $69.4M.
  • Sofinnova Investments fully exited Vertex Pharmaceuticals in Q1 2026, selling an estimated $74.6M.
  • Sofinnova Investments's ten largest holdings make up 49% of its $2.63B portfolio in Q1 2026.
  • Sofinnova Investments opened 29 new positions and closed 15 in Q1 2026.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $2.63B.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.